China In Vitro Diagnostics Market 2021-2026: Focus on Clinical Chemistry, Immunoassays, Microbiology and Molecular Testing, POC Testing and Histology/Cytology - ResearchAndMarkets.com
As an in vitro diagnostics (IVD) market, China trails only the populous, developed economy markets of the United States, western European countries, and Japan. The country and its healthcare system are confronted by challenges shared by less developed countries, but also burdens common among developed middle-income and affluent countries such as diabetes, cardiovascular disease, and diseases of aging.
China as an IVD market opportunity is defined by its standing next to other populous countries with demonstrated economic promise for over the past decade - Brazil, Russia and India (collectively with China referred to as the important, rapidly growing "BRIC" nations).
The report, In Vitro Diagnostic (IVD) Markets in China, 2021, is designed to provide the reader with an overview of the Chinese laboratory market and its influences. The focus is on the IVD discipline including reagents, consumables, calibrators and controls of the following sub-segments:
Clinical Chemistry: routine lab testing; substrates, enzymes, homogeneous immunoassays, proteins, ISE (non-POC), HBA1c (non-POC), includes urinalysis and blood chemistry testing.
Immunoassays: hormones and thyroid function, tumor markers, allergy, anemia, neonatal tests, prenatal tests, interleukins, PCT, toxicology and common infectious diseases (HIV, hepatitis, influenza)
Microbiology and Molecular Testing: manual and automated tests, culture media (to be prepared or ready to use), latex tests, transport media, blood culture, sensitivity discs, Gram and other stains, MTB culture, Mycoplasma, Ureaplasma, nucleic acid testing.
Point-of-Care Testing: all POC tests for cardiology, toxicology, coagulation, diabetes, infectious diseases, including POC and non-POC blood gas and electrolytes, and glucose self-monitoring tests.
Histology/Cytology: PAP, HE, IHC, ISH, FISH, primary and secondary antibodies.
Included in the report are trends influencing the industry and country-level data including the incidence of disease, life expectancy, population demographics, economic status, healthcare utilization and other market influences.
All market data pertains to the IVD market in China at the manufacturers' level. Market data is presented for the 2021 year with forecast data provided for 2026. Compound annual growth rates (CAGRs) are provided for the 2021-2026 period.
Key Topics Covered:
Chapter one: Executive Summary
Scope and methodology
Major findings of the report
IVD market in china
Chapter two: China in context
Overview
Population trends
Disease demographics
Infectious disease threats
Chinese economy
Chapter three: Clinical laboratory structure in china
Clinical laboratory tests
Chinese healthcare reform and hospital infrastructure
China regulation and medical device policy challenges
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Zhihu Inc. ("Zhihu" or the "Company") , a leading online content community in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission on April 26,...
Hisense, a leading global provider of consumer electronics and premium home appliances, has today announced the launch of the groundbreaking 7S Smart Laundry Washer & Dryer in the MENA region. This innovative appliance is designed to elevate laundry...
XTX Markets' newly created Artificial Intelligence Mathematical Olympiad Prize ('AIMO Prize') is a $10mn challenge fund designed to spur the creation of a publicly shared AI model capable of winning a gold medal in the International Mathematical...
Elastic , the company behind Elasticsearch®, today announced new vector database performance gains with Elasticsearch and Apache Lucene, with up to 8x speed and 32x efficiency. These advancements provide developers with the most flexible and open...
On April 19th, the results of the "2024 Forbes China Bold Pioneers Selection" were officially announced. Mario Ho, Chairman and co-CEO of NIP Group, was among the selected, along with Miranda Qu Fang, co-founder and president of the Chinese social...
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major...